Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $12.2500 (1.16%) ($11.9200 - $12.2600) on Fri. Oct. 16, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.76% (three month average) | RSI | 43 | Latest Price | $12.2500(1.16%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.2% a day on average for past five trading days. | Weekly Trend | AUTL advances 2.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(14%) IBB(13%) SKYY(13%) ARKG(12%) BLOK(12%) | Factors Impacting AUTL price | AUTL will decline at least -1.88% in a week (0% probabilities). TBT(-9%) VIXM(-8%) UNG(-6%) USO(-5%) IGOV(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.88% (StdDev 3.76%) | Hourly BBV | 0 () | Intraday Trend | 0.1% | | | |
|
Resistance Level | $12.33 | 5 Day Moving Average | $12.42(-1.37%) | 10 Day Moving Average | $12.31(-0.49%) | 20 Day Moving Average | $12.33(-0.65%) | To recent high | -24.8% | To recent low | 10.5% | Market Cap | $640m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |